Masterclass Speakers

Manuel Bardies

Manuel Bardiès obtained his Doctorate on radiopharmaceutical dosimetry from Toulouse University, France in 1991. He has been developing his research in radiopharmaceutical dosimetry within INSERM (National Institute of Health and Medical Research) since 1992 in Nantes, then in Toulouse (2011), and currently in Montpellier (2021-).

Professor Bardiès was one of the founders of the EANM Dosimetry Committee (member from 2001 to 2013, chair 2009 to 2011). He chaired EFOMP Science Committee between 2014 and 2016 and is currently chairing the newly established EFOMP Special Interest Group for radionuclide internal dosimetry.

He has been involved in education in various European structures (ESMIT, ESMPE). He is a member of the Board of the medical physics resident program in France and was appointed Professor by the French National Institute for Nuclear Science and Technology (INSTN) in June 2018.

The group led by Professor Bardiès is primarily involved in radiopharmaceutical dosimetry, at various scales (cell, tissue, organ). This requires the ability to assess radiopharmaceutical pharmacokinetics in vivo, through quantitative SPECT or PET small-animal imaging, or in the clinics. An important part of the research activity involves Monte Carlo modelling of radiation transport. The objective is to improve molecular radiotherapy by allowing patient-specific treatments (personalised medicine).

Anita Brink

Anita Brink obtained her MBChB degree from the University of Pretoria in 1999. She qualified as a Nuclear Physician in 2007. In 2010 she was awarded her Master’s Degree in Nuclear Medicine with a distinction for the dissertation. In 2020 she was awarded a PhD in Nuclear Medicine.

Since 2009 Dr Brink has been the Operational Head of the Nuclear Medicine Department at Red Cross War Memorial Children’s Hospital. She has published a number of articles in the field of Paediatric Nuclear Medicine as well as a chapter in a book. Her main field of interest is paediatric renography.

Joel Dave

Joel Dave is Head of the Division of Endocrinology at Groote Schuur Hospital and the University of Cape Town, a busy division with multiple clinics covering all aspects of endocrinology and with referral of complex clinical cases. Professor Dave is involved in a multi-disciplinary Neuroendocrine Tumour Clinic with surgical and nuclear medicine colleagues at Groote Schuur Hospital.

Bawinile Hadebe

Bawinile Hadebe is the Clinical Head of the Nuclear Medicine Department at Inkosi Albert Luthuli Central Hospital and Honorary Lecturer at the University of KwaZulu-Natal. She serves as a council member at the College of Nuclear Physicians.

Dr Hadebe obtained her MBChB degree from the University of Cape Town in 2007. She qualified as a Nuclear Physician in 2015. In 2017 she was awarded her Master’s Degree in Nuclear Medicine with a distinction for the dissertation. She is currently reading for her PhD in Nuclear Medicine. Her main field of interest is nuclear oncology and targeted radionuclide therapies.

Greg Hart

Greg Hart is a Clinical Oncologist working in private practice in the Cancercare group based in the Southern Suburbs of Cape Town.

He performed his undergraduate studies at the University of the Witwatersrand followed by an Internship at the Chris Hani Baragwanath Hospital. He then lived and worked in the UK for 5 years and it was here that his interest in Oncology began. He made the decision to return to South Africa in 2000 and took up a Registrar post at Groote Schuur Hospital. He was admitted as a Fellow of the College of Radiation Oncologists in October 2004. Dr Hart then headed up the Lung and Urology Clinics at the Dept of Radiation Oncology at Groote Schuur for a year before moving to full-time Private Practice in 2006.

Dr Hart has an interest in Urological Cancers, Breast Cancer, Lung Cancer and Sarcomas and is a regular attendee at the local Multi-Disciplinary Meetings both in the Public and Private sectors.

Dr Hart is member of the South African Society of Radiation Oncologists and served on it’s Executive Committee from 2011 – 2019.

Dr Hart is involved in a number of Industry -Sponsored Clinical Trials, both as a Principal Investigator and Sub-Investigator. He is an Honorary Lecturer in the Department of Radiation Oncology at the University of Cape Town

Ken Herrman

Ken Herrmann currently acts as Chair of the Department of Nuclear Medicine at the Universitätsklinikum Essen in Germany, is Chair of the EANM Oncology and Theranostics Committee, and serves as a Section Editor of The Journal of Nuclear Medicine. Professor Herrmann’s earlier career found him as a Visiting Assistant Professor promoted to Associate Professor in the Ahmanson Translational Imaging Division of the Department of Molecular and Medical Pharmacology at the University of California Los Angeles in addition to holding his position as Vice Chair of the Department of Nuclear Medicine at the Universitätsklinikum Würzburg.

Professor Herrmann holds a Doctorate Degree from Humboldt Universität Berlin and completed his residency in Nuclear Medicine at Klinikum rechts der Isar, Technische Universität München in addition to his MBA, which he received from the Universität Zürich, Switzerland in 2011.

Rob Hobbs

Rob Hobbs is an Associate Professor and ABR-certified Medical Physicist in the Department of Radiation Oncology and Molecular Radiation Sciences with secondary appointments in Nuclear Medicine and in Oncology.

Dr. Hobbs earned his undergraduate degrees (DEUG, Licence, Maîtrise) in physics from the Université Louis Pasteur in Strasbourg, France, with a year spent at the Universität Wien (Vienna, Austria) as an ERASMUS exchange student. He earned his Ph.D. from the University of New Mexico in high energy physics before joining the Radiopharmaceutical Therapy and Dosimetry lab as a post-doc in 2006 at Johns Hopkins. In 2011, he joined the department of Radiation Oncology as a Medical Physics resident. He completed his residency in 2013 and has since held a dual appointment with a 50% clinical component. His research focusses on targeted alpha-particle therapy and dosimetry, as well as personalized dosimetry-based treatment planning for radiopharmaceutical therapy and combined modalities. Dr. Hobbs is an elected member of the MIRD (Medical Internal Radiation Dose) Committee, chairs the AAPM sub-committee on Radiopharmaceutical Therapy and is a member of a variety of committees and task forces for a range of societies such as ICRU, IAEA, SNMMI, ASTRO, NCI.

Gunjan Kayal

Gunjan Kayal obtained her Doctorate degree from the University of Toulouse, France. During these years she was jointly working in the Cancer Research Centre of Toulouse INSERM (France) and Belgian Nuclear Research Center SCK CEN (Belgium) on an existing project – DosiTest – which aims to evaluate the impact of the various steps that contribute to the realisation of a dosimetric study (from scintigraphic SPECT/CT imaging to absorbed dose calculation), by means of a virtual multicentric intercomparison based on GATE Monte Carlo modelling.

Dr Kayal has been involved in an IAEA Co-ordinated Research Project (E23005) on "Dosimetry in radiopharmaceutical therapy for personalised patient treatment" to perform clinical dosimetry analysis and generate simulated clinical patient datasets (SPECT/CT) based on GATE Monte Carlo modelling in Molecular Radiotherapy (MRT). Along with this, she was a part of the Joint Research European Project "MRT Dosimetry" and contributed towards the modelling of SPECT imaging in GATE along with the generation of time-variable activity distribution in multimodal imaging (SPECT/CT).

Prior to her PhD, Dr Kayal received her joint Master’s Degree in Ionising Radiations and Medical Applications from IMT Atlantique Nantes and ENSICaen, France. She has published various articles and has also been involved in writing a chapter in the book Volume II: Dosimetry and Radiation Protection, Handbook of Nuclear Medicine and Molecular Imaging for Physicists.

Her interest lies in the dosimetry in radiopharmaceutical therapy. Dr Kayal is joining the Department of Radiology at the University of Michigan as a Postdoctoral Research Fellow and will participate in radiation dosimetry, Monte Carlo simulation of medical imaging systems, quantitative SPECT, and PET imaging and reconstruction.

Michael Mix

Michael Mix received his diploma and his PhD from the Faculty of Physics at the Albert-Ludwigs-University of Freiburg, Germany. He completed his graduation as medical physicist at the University of Kaiserslautern, Germany and received his accreditation from the German Society of Medical Physics in 2002 for nuclear medicine and image processing. He holds the registration as a qualified medical physics expert in nuclear medicine and radiology from the German government and he has the authorisation for advanced training in medical physics.

Currently, Professor Mix is head of the medical physics group and Academic Director at the Department of Nuclear Medicine, Medical Center, University of Freiburg. Since 2016 he has associated with the Division of Nuclear Medicine at Tygerberg Hospital as an Extraordinary Professor at Stellenbosch University.

He has extensive experience in PET/CT and SPECT/CT and radionuclide therapy with I-131 as well as with Lu-177 for RLT and PRRT. In numerous research projects, he is responsible for quantitative data analysis and the optimisation of biological imaging with new tracers, especially for its use in therapy planning, monitoring, and for dosimetry.

Stuart More

Stuart More is the Acting Head of Division of Nuclear Medicine at Groote Schuur Hospital and University of Cape Town and the current President of the South African Society of Nuclear Medicine (SASNM). He also serves as the Communications Director at the South African Clinician Scientists’ Society and Co-ordinator of the National Working Group in Radiosynoviorthesis at the Medical and Scientific Advisory Council. He completed his undergraduate degree at the University of the Witwatersrand in 2008, and completed his nuclear medicine training at the University of Cape Town and Red Cross War Memorial Children’s Hospital/Groote Schuur Hospital complex in 2017. He is currently a PhD candidate at the University of Pretoria/Nuclear Medicine Research Infrastructure (NuMeRI).

Dr More’s interest in the promotion, development, and advocacy of nuclear medicine, molecular imaging, and theranostics at all levels have allowed him to collaborate with multiple stakeholders in advancing the future of the field, particularly in the direction theranostics is taking in South Africa and globally.

Shingai Mutambirwa

Shingai Mutambirwa holds M Med (Urology) Medunsa and FCS (Urol) degrees, qualifying in 1996. He is Head of Department of Urology at Dr George Mukhari Academic Hospital and Sefako Makgatho Health Sciences University in Pretoria South Africa from 2008 to date where he teaches post- and undergraduate medical/urology students.

Professor Mutambirwa is a Peer Reviewer for The Journal of Urology (official journal of the American Urological Association), The African Journal of Urology, and Hindawi online publications. He has published more than 80 peer reviewed articles and 10 book chapters.

His board membership includes the Prostate Cancer Foundation of South Africa (founding member), and Senator (Urology) for the Colleges of Medicine of South Africa (CMSA).

He participates on advisory boards and as a key opinion leader for Aspen, Astellas, Jansen (J&J), Bayer, Schering Pharma, Pfizer, Eli Lilly, Abbott, Schering-Plough, Ferring, and Adcock Ingram.

Mike Sathegke

Mike Sathekge is a Professor and Head of the Nuclear Medicine Department at the University of Pretoria and Steve Biko Academic Hospital. He heads the South African Nuclear Medicine Research Infrastructure.

Professor Sathekge has published more than 220 peer-reviewed articles, excluding abstracts and book chapters. He is one of the global leaders concerning treatment of prostate cancer using targeted radiopharmaceuticals. He also led and introduced several targeted molecular imaging and therapeutic probes in infection and oncology in Africa. He is the Editor-in-Chief of Seminars in Nuclear Medicine and an Associate Editor of The European Journal of Nuclear Medicine and Molecular Imaging and The Journal of Nuclear Medicine (top journals in nuclear medicine). 

Professor Sathekge is President of the World Association of Radiopharmaceuticals and Molecular Therapy, the Past Chair of the South African Medical Research Council, and the Past President of the Colleges of Medicine of South Africa (CMSA). Some of his significant awards include the award to host the main Nuclear Medicine Research Infrastructure facility (NuMeRI) in South Africa, the South African Clinician Society Research Excellence Award, the Fellowship in Art and Science of Medicine Award, the Golden Pen Award, the SAMA Leadership Award, and the prestigious Medical Research Council President’s Award for Exceptional Lifelong Contribution to Medical Research and Public Health.

Professor Sathekge is the chair of the ASSAf panel on research, development, and innovation of peaceful uses of nuclear technologies in South Africa. He holds the highest honour of the CMSA – Honorary Fellowship – and he was also honoured by being admitted as a Fellow of the Academy of Medicine, Singapore.

Graham Stapleton

Graham Stapleton qualified M.B.Ch.B. at the University of Cape Town in 1978 and obtained the F.C.S. (SA) in general surgery in 1989 after training at Groote Schuur Hospital. He obtained a M.Med degree for research into gastric mucus in a porcine peptic ulcer model, was a research fellow in the UCT/MRC Liver Centre for 1990, and was registered for a Ch.M., publishing on the blood supply of the intrahepatic bile ducts and on hepatic blood flow in pigs after reduced liver transplants

Dr Stapleton then worked as a Junior Consultant at Groote Schuur Hospital from 1991 to 1993, for Professor Dent (surgical oncology and surgical endocrinology) in 1991, for Professors Terblanche, Bornman, and Krige (hepato-pancreato-biliary and upper GI surgery) in 1992, and Professor Immelman (vascular surgery) in 1993.

From 1993 to 1994 he worked as Overseas Senior Registrar at the Royal Victoria and Belfast City Hospitals (Queens University) in Belfast, Northern Ireland and from 1994 to 1995 as Overseas Senior Registrar at the Hammersmith Hospital (Royal Postgraduate Medical School), gaining further specialised training in hepato-pancreato-biliary surgery, surgical oncology, surgical endocrinology, upper GI surgery, and laparoscopic surgery.

Dr Stapleton joined the IHPBA in 1994 and the EHPBA in 1995 and has been a member continuously since then. He returned to Cape Town in 1995 and started in private practice at the Clinic Holdings Wynberg Hospital. He was appointed to a part-time consultant post in Professor Bornman’s firm at Groote Schuur Hospital in 1996 and continued in that post until 2006.

In 2000 Dr Stapleton moved his practice to Kingsbury Hospital in Claremont, where he established a practice based on hepatobiliary and pancreatic surgery and advanced laparoscopic surgery. He also worked in close association with Dr Michael Elliot, assisting him with complex colorectal and pelvic floor surgery.

In the late 1990s Dr Stapleton set up The Gut Club, a multi-disciplinary group spanning private and public service specialists for monthly continuing medical education meetings in various aspects of gastroenterology. He joined ENETS after attending their meeting in Krakow, Poland in about 2003 and has continued to be a member since then.

In 2005 he set up a multidisciplinary team for treating morbid obesity and started doing laparoscopic metabolic (bariatric) surgery. He subsequently participated in setting up multi-disciplinary teams for managing patients with colorectal and other GIT cancers and then a separate group for treating gastroenterological and pancreatic neuroendocrine tumours (GEPNETs). The latter also involved pushing for the introduction of DOTA PET scans at Tygerberg Hospital and the establishment of SIRT (hepatic arterial radioembolisation) and peptide receptor radiation therapy (PRRT).

He was a founder member of the HPBASA and served on its executive for several years, culminating in serving as president in 2017-18.

In 2017 Dr Stapleton relocated his practice to the new Netcare Christiaan Barnard Memorial Hospital on the Foreshore of Cape Town and he continues to work there now.

Waldemar Szpak

Waldemar Szpak is a clinical radiation oncologist in Durban who opened his own private practice, Rainbow Oncology, that has been treating patients since 2010. He has a considerable and noteworthy background medical field, having graduated from Warsaw University in the Internal Medicine discipline, and gained a wealth of experience in many European countries in this field, before emigrating to South Africa in 1992.

He was co-running  Coronary Care Unit at Addington Hospital in Durban and subsequently specialised in Clinical Oncology at the University of Kwa-Zulu Natal. Dr Szpak returned to the United Kingdom thereafter, where he worked as Clinical Oncologist in Newcastle before returning to South Africa, when he opened Rainbow Oncology. His vast experience in the medical profession, astute clinical knowledge, his passion for Oncology, and great moral standing has led to his success in his practise, as well as being a member or consultant in numerous national and international Oncology organisations.

Tumelo Carel Godwin Moalosi

Tumelo Carel Godwin Moalosi obtained his BSc Honours degree from North-West University in Mafikeng. He further graduated with Master of Science in Medical Physics at Stellenbosch University, focussing his research on “Reconstruction algorithms for quantification of FDG PET brain imaging”. Dr Moalosi’s interest is in nuclear medicine imaging and non-imaging equipment quality control and optimisation. He is also an expert in nuclear medicine quantification imaging.

Throughout his work experience he has gained several fellowships with IAEA to be trained in some of the international nuclear medicine departments, e.g., the Royal North Shore Hospital in Sydney (Australia) under the guidance of Professor Dale Bailey, and in Freiburg University Hospital in Germany under the guidance of Professor Michael Mix. Dr Moalosi has served as a chief scientific investigator for IAEA CRP E2.30.05 project on “Dosimetry in Radiopharmaceutical Therapy for Personalized Patient Treatment”. He has also contributed to a book “Establishing of a quality control program in single photon emission computed tomography in Africa” under IAEA project RAF 6/053.

Dr Moalosi is currently a senior lecturer at Stellenbosch University, an examiner for the College of Medicine of South Africa (CMSA) for nuclear physicians, and a manager of the Nuclear Medicine Department in the Medical Physics Division at Tygerberg Hospital.

Mariza Vorster

Mariza Vorster is an Associate Professor and Head of Clinical Department at the University of KwaZulu-Natal’s Department of Nuclear Medicine. She is the current President of the Colleges of Nuclear Physicians and serves on the management committee of the Colleges of Medicine of South Africa's (CMSA) Examinations and Credentials Committee.

Professor Vorster qualified as a nuclear medicine physician in 2010 at the University of Pretoria. She subsequently obtained her PhD in 2014 (from the University of Pretoria) on the use of 68Ga-citrate PET in indeterminate lung lesions and became the first female nuclear physician with a PhD in South Africa. She is an NRF-rated scientist who has authored and co-authored more than 100 peer-reviewed publications, which include several textbook chapter contributions.

Professor Vorster is passionate about training well-rounded nuclear medicine physicians who are sought after globally and improving access to nuclear medicine facilities locally. Internationally, she has collaborated with the International Atomic Energy Association (IAEA) on several projects and has been involved in the co-ordination of, and teaching of, various workshops aimed at the training of radiographers and nuclear physicians from across the African continent.

Her research interests include the use of novel Ga-68 based tracer applications and theranostics that are aimed at solving important clinical problems. She aspires to make a meaningful difference by addressing diagnostic challenges that are unique to the South African setting in a cost-effective way.